REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
2. Nie Y, Li D, Peng Y, et al. Metal organic framework coated MnO2 nanosheets delivering doxorubicin and self-activated DNAzyme for chemo-gene combinatorial treatment of cancer. Int J Pharm 2020;585:119513.
3. Chen J, Wang X, Yuan Y, et al. Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair-inhibiting (HYDRI) nanomedicine. Sci Adv 2021;7:eabc5267.
4. Jiang Q, Zhang M, Sun Q, Yin D, Xuan Z, Yang Y. Enhancing the antitumor effect of doxorubicin with photosensitive metal-organic framework nanoparticles against breast cancer. Mol Pharm 2021;18:3026-36.
5. Li H, Zhang Y, Liang L, et al. Doxorubicin-loaded metal-organic framework nanoparticles as acid-activatable hydroxyl radical nanogenerators for enhanced chemo/chemodynamic synergistic therapy. Materials 2022;15:1096.
6. Koppula P, Lei G, Zhang Y, et al. A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. Nat Commun 2022;13:2206.
7. Pan Q, Xie L, Liu R, et al. Two birds with one stone: copper metal-organic framework as a carrier of disulfiram prodrug for cancer therapy. Int J Pharm 2022;612:121351.
8. Wang F, Huang J, Xin H, Lei J. Triple-layered metal-organic framework hybrid for tandem response-driven enhanced chemotherapy. Chem Asian J 2021;16:2068-74.
9. Li J, Yuan D, Zheng X, Zhang X, Li X, Zhang S. A triple-combination nanotechnology platform based on multifunctional RNA hydrogel for lung cancer therapy. Sci China Chem 2020;63:546-53.
10. Hao K, Lin L, Sun P, et al. Cationic flexible organic framework for combination of photodynamic therapy and genetic immunotherapy against tumors. Small 2021;17:e2008125.
11. Zhang L, Li Y, Hu C, et al. CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells. Mol Cancer 2022;21:103.
12. Liu Y, Li X, Shi Y, et al. Two-dimensional intermetallic PtBi/Pt core/shell nanoplates overcome tumor hypoxia for enhanced cancer therapy. Nanoscale 2021;13:14245-53.
13. Geng Z, Wang L, Liu K, Liu J, Tan W. Enhancing anti-PD-1 immunotherapy by nanomicelles self-assembled from multivalent aptamer drug conjugates. Angew Chem Int Ed 2021;60:15459-65.
14. Yi X, Zhou H, Chao Y, et al. Bacteria-triggered tumor-specific thrombosis to enable potent photothermal immunotherapy of cancer. Sci Adv 2020;6:eaba3546.
15. Wu J, Zhu MX, Li KS, Peng L, Zhang PF. Circular RNA drives resistance to anti-PD-1 immunotherapy by regulating the miR-30a-5p/SOX4 axis in non-small cell lung cancer. Cancer Drug Resist 2022;5:261-70.
17. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714-26.
18. Wang H, Agarwal P, Zhao G, et al. Overcoming ovarian cancer drug resistance with a cold responsive nanomaterial. ACS Cent Sci 2018;4:567-81.
19. Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol 2021;14:85.
20. Luo X, Zhang Q, Chen H, Hou K, Zeng N, Wu Y. Smart nanoparticles for breast cancer treatment based on the tumor microenvironment. Front Oncol 2022;12:907684.
21. Hou DY, Xiao WY, Wang JQ, et al. OGA activated glycopeptide-based nano-activator to activate PKM2 tetramerization for switching catabolic pathways and sensitizing chemotherapy resistance. Biomaterials 2022;284:121523.
22. Qin L, Cao J, Shao K, et al. A tumor-to-lymph procedure navigated versatile gel system for combinatorial therapy against tumor recurrence and metastasis. Sci Adv 2020;6:eabb3116.
23. Liang M, Fan K, Zhou M, et al. H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection. Proc Natl Acad Sci U S A 2014;111:14900-5.
24. Zhu L, Shi Y, Xiong Y, et al. Emerging self-assembling peptide nanomaterial for anti-cancer therapy. J Biomater Appl 2021;36:882-901.
25. Li D, Lin L, Fan Y, et al. Ultrasound-enhanced fluorescence imaging and chemotherapy of multidrug-resistant tumors using multifunctional dendrimer/carbon dot nanohybrids. Bioact Mater 2021;6:729-39.
26. Hu Y, Mignani S, Majoral JP, Shen M, Shi X. Construction of iron oxide nanoparticle-based hybrid platforms for tumor imaging and therapy. Chem Soc Rev 2018;47:1874-900.
27. Chenyang Y, Fang Y, Li S, et al. Magnetically switchable mechano-chemotherapy for enhancing the death of tumour cells by overcoming drug-resistance. Nano Today 2020;35:100967.
28. Yang B, Zhou S, Zeng J, et al. Super-assembled core-shell mesoporous silica-metal-phenolic network nanoparticles for combinatorial photothermal therapy and chemotherapy. Nano Res 2020;13:1013-9.
29. Xia Y, Rao L, Yao H, Wang Z, Ning P, Chen X. Engineering macrophages for cancer immunotherapy and drug delivery. Adv Mater 2020;32:e2002054.
30. Liu B, Ma R, Zhao J, Zhao Y, Li L. A smart DNA nanodevice for ATP-activatable bioimaging and photodynamic therapy. Sci China Chem 2020;63:1490-7.
31. Hu XY, Song Z, Yang ZW, Li JJ, Liu J, Wang HS. Cancer drug resistance related microRNAs: recent advances in detection methods. Analyst 2022;147:2615-32.
32. Gautam M, Poudel K, Yong CS, Kim JO. Prussian blue nanoparticles: synthesis, surface modification, and application in cancer treatment. Int J Pharm 2018;549:31-49.
33. Lian X, Huang Y, Zhu Y, et al. Enzyme-MOF nanoreactor activates nontoxic paracetamol for cancer therapy. Angew Chem Int Ed 2018;57:5725-30.
34. Ni D, Lin J, Zhang N, et al. Combinational application of metal-organic frameworks-based nanozyme and nucleic acid delivery in cancer therapy. WIREs Nanomed Nanobi 2022;14:e1773.
35. Chen Z, Liu M, Zhang M, et al. Interfering with lactate-fueled respiration for enhanced photodynamic tumor therapy by a porphyrinic MOF nanoplatform. Adv Funct Mater 2018;28:1803498.
36. Hu L, Xiong C, Wei G, et al. Stimuli-responsive charge-reversal MOF@polymer hybrid nanocomposites for enhanced co-delivery of chemotherapeutics towards combination therapy of multidrug-resistant cancer. J Colloid Interface Sci 2022;608:1882-93.
37. Wu Q, Du Q, Sun X, et al. MnMOF-based microwave-glutathione dual-responsive nano-missile for enhanced microwave Thermo-dynamic chemotherapy of drug-resistant tumors. Chem Eng J 2022;439:135582.
38. Sun X, Li Y, Xu L, et al. Heparin coated meta-organic framework co-delivering doxorubicin and quercetin for effective chemotherapy of lung carcinoma. J Int Med Res 2020;48:300060519897185.
39. Du B, Zheng M, Ma H, et al. Nanozyme-natural enzymes cascade catalyze cholesterol consumption and reverse cancer multidrug resistance. J Nanobiotechnology 2022;20:209.
40. Wang JW, Chen QW, Luo GF, et al. A self-driven bioreactor based on bacterium-metal-organic framework biohybrids for boosting chemotherapy via cyclic lactate catabolism. ACS Nano 2021;15:17870-84.
41. Tong PH, Zhu L, Zang Y, Li J, He XP, James TD. Metal-organic frameworks (MOFs) as host materials for the enhanced delivery of biomacromolecular therapeutics. Chem Commun 2021;57:12098-110.
42. Wang Z, Niu J, Zhao C, Wang X, Ren J, Qu X. A bimetallic metal-organic framework encapsulated with DNAzyme for intracellular drug synthesis and self-sufficient gene therapy. Angew Chem Int Ed 2021;60:12431-7.
43. Li L, Muñoz-Culla M, Carmona U, et al. Ferritin-mediated siRNA delivery and gene silencing in human tumor and primary cells. Biomaterials 2016;98:143-51.
44. Du L, He H, Xiao Z, et al. GSH-responsive metal-organic framework for intratumoral release of NO and IDO inhibitor to enhance antitumor immunotherapy. Small 2022;18:e2107732.
45. Yang H, Zhang Y, Zeng L, et al. Cell-selective encapsulation within metal-organic framework shells via precursor-functionalized aptamer identification for whole-cell cancer vaccine. Small Methods 2022;6:e2101391.
46. Xu M, Hu Y, Ding W, et al. Rationally designed rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance. Biomaterials 2020;258:120308.
47. Li F, Chen T, Wang F, et al. Enhanced cancer starvation therapy enabled by an autophagy inhibitors-encapsulated biomimetic ZIF-8 nanodrug: disrupting and harnessing dual pro-survival autophagic responses. ACS Appl Mater Interfaces 2022;14:21860-71.
48. Han H, Hou Y, Chen X, et al. Metformin-induced stromal depletion to enhance the penetration of gemcitabine-loaded magnetic nanoparticles for pancreatic cancer targeted therapy. J Am Chem Soc 2020;142:4944-54.
49. Xin X, Kumar V, Lin F, et al. Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy. Sci Adv 2020;6:eabd6764.
50. Chen J, Nie W, Hu Y, et al. A folic acid-modified non-viral vector combines gene therapy with chemotherapy to reverse cancer chemotherapy resistance. Appl Mater Today 2022;26:101277.
51. Chen K, Qian W, Jiang Z, et al. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol Cancer 2017;16:131.
52. Ruan L, Chen J, Du C, et al. Mitochondrial temperature-responsive drug delivery reverses drug resistance in lung cancer. Bioact Mater 2022;13:191-9.
53. Ortiz M, Wabel E, Mitchell K, Horibata S. Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist 2022;5:304-16.
54. Wang MM, Xu FJ, Su Y, et al. A new strategy to fight metallodrug resistance: mitochondria-relevant treatment through mitophagy to inhibit metabolic adaptations of cancer cells. Angew Chem Int Ed 2022;61:e202203843.
55. Peng H, Zhang X, Yang P, et al. Defect self-assembly of metal-organic framework triggers ferroptosis to overcome resistance. Bioact Mater 2023;19:1-11.
56. Wang K, Jiang M, Zhou J, Liu Y, Zong Q, Yuan Y. Tumor-acidity and bioorthogonal chemistry-mediated on-site size transformation clustered nanosystem to overcome hypoxic resistance and enhance chemoimmunotherapy. ACS Nano ;2022:721-35.
57. Baek S, Yu SE, Deng Y, et al. Quenching epigenetic drug resistance using antihypoxic microparticles in glioblastoma patient-derived chips. Adv Healthcare Materials 2022;11:2102226.
58. Yamamoto K, Venida A, Yano J, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 2020;581:100-5.
59. Lopez A, Reyna DE, Gitego N, et al. Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer. Nat Commun 2022;13:1199.
60. Qi Z, Xu Z, Zhang L, et al. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment. Nat Commun 2022;13:182.
61. Wu S, Cao R, Tao B, et al. Pyruvate facilitates FACT-mediated γH2AX loading to chromatin and promotes the radiation resistance of glioblastoma. Adv Sci 2022;9:e2104055.
62. Chen Q, Xu M, Zheng W, Xu T, Deng H, Liu J. Se/Ru-decorated porous metal-organic framework nanoparticles for the delivery of pooled siRNAs to reversing multidrug resistance in taxol-resistant breast cancer cells. ACS Appl Mater Interfaces 2017;9:6712-24.
63. Caushi JX, Zhang J, Ji Z, et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature 2021;596:126-32.
64. Joung J, Kirchgatterer PC, Singh A, et al. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nat Commun 2022;13:1606.
65. Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol 2022;23:660-70.
66. Mair F, Erickson JR, Frutoso M, et al. Extricating human tumour immune alterations from tissue inflammation. Nature 2022;605:728-35.
67. Guo Y, Lu X, Chen Y, et al. Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells. Sci Adv 2021;7:eabd7455.
68. Mirzaei R, Gordon A, Zemp FJ, et al. PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway. Sci Adv 2021;7:eabh2148.
69. Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 2020;367:eaax0182.
70. Xie X, Feng Y, Zhang H, et al. Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy. Bioact Mater 2022;16:107-19.
71. Liu M, Kuo F, Capistrano KJ, et al. TGF-β suppresses type 2 immunity to cancer. Nature 2020;587:115-20.
72. Lv J, Liu Y, Mo S, et al. Gasdermin E mediates resistance of pancreatic adenocarcinoma to enzymatic digestion through a YBX1-mucin pathway. Nat Cell Biol 2022;24:364-72.
73. Ulldemolins A, Seras-Franzoso J, Andrade F, et al. Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics. Cancer Drug Resist 2021;4:44-68.
74. Wang W, Wang J, Liu S, et al. An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer. Mol Cancer 2022:21.
75. Zhang LX, Gao J, Long X, et al. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis. Mol Cancer 2022;21:110.
76. Jiang J, Wang W, Zheng H, et al. Nano-enabled photosynthesis in tumours to activate lipid peroxidation for overcoming cancer resistances. Biomaterials 2022;285:121561.
77. Aldonza MBD, Ku J, Hong JY, et al. Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms. Sci Adv 2020;6:eaav7416.
78. Tiek D, Cheng SY. DNA damage and metabolic mechanisms of cancer drug resistance. Cancer Drug Resist 2022;5:368-79.
79. Serratì S, Guida M, Di Fonte R, et al. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Mol Cancer 2022;21:20.
80. Saha B, Mathur T, Tronolone JJ, et al. Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer. Sci Adv 2021;7:eabg5283.
81. Wang X, Zhao S, Wang Z, Gao T. Platelets involved tumor cell EMT during circulation: communications and interventions. Cell Commun Signal 2022;20:82.
82. Cai G, Yan P, Zhang L, Zhou HC, Jiang HL. Metal-organic framework-based hierarchically porous materials: synthesis and applications. Chem Rev 2021;121:12278-326.
83. Ren H, Wei T. Electrochemical synthesis methods of metal-organic frameworks and their environmental analysis applications: a review. ChemElectroChem 2022:9.
84. Zhuang J, Kuo CH, Chou LY, Liu DY, Weerapana E, Tsung CK. Optimized metal-organic-framework nanospheres for drug delivery: evaluation of small-molecule encapsulation. ACS Nano 2014;8:2812-9.
85. Liang K, Ricco R, Doherty CM, et al. Biomimetic mineralization of metal-organic frameworks as protective coatings for biomacromolecules. Nat Commun 2015;6:7240.
86. Peng S, Bie B, Sun Y, et al. Metal-organic frameworks for precise inclusion of single-stranded DNA and transfection in immune cells. Nat Commun 2018;9:1293.
87. Haydar M, Abid HR, Sunderland B, Wang S. Metal organic frameworks as a drug delivery system for flurbiprofen. Drug Des Devel Ther 2017;11:2685-95.
88. Yang Y, Chen Q, Wu JP, et al. Reduction-responsive codelivery system based on a metal-organic framework for eliciting potent cellular immune response. ACS Appl Mater Interfaces 2018;10:12463-73.
89. Zhao M, Ban Y, Yang W. Assembly of ionic liquid molecule layers on metal-organic framework-808 for CO2 capture. Chem Eng J 2022;439:135650.
90. Jiang S, Guo L, Chen L, et al. A strongly hydrophobic ethane-selective metal-organic framework for efficient ethane/ethylene separation. Chem Eng J 2022;442:136152.
91. Yu K, Wei T, Li Z, Li J, Wang Z, Dai Z. Construction of molecular sensing and logic systems based on site-occupying effect-modulated MOF-DNA interaction. J Am Chem Soc 2020;142:21267-71.
92. Gao H, Wei X, Li M, Wang L, Wei T, Dai Z. Co-quenching effect between lanthanum metal-organic frameworks luminophore and crystal violet for enhanced electrochemiluminescence gene detection. Small 2021;17:e2103424.
93. Jiang ZW, Zhao TT, Li CM, Li YF, Huang CZ. 2D MOF-based photoelectrochemical aptasensor for SARS-CoV-2 spike glycoprotein detection. ACS Appl Mater Interfaces 2021;13:49754-61.
94. Li Y, Zhang C, He Y, et al. A generic and non-enzymatic electrochemical biosensor integrated molecular beacon-like catalyzed hairpin assembly circuit with MOF@Au@G-triplex/hemin nanozyme for ultrasensitive detection of miR-721. Biosens Bioelectron 2022;203:114051.
95. Sharabati M, Sabouni R, Husseini GA. Biomedical applications of metal-organic frameworks for disease diagnosis and drug delivery: a review. Nanomaterials 2022;12:277.
96. Ni W, Wu J, Fang H, et al. Photothermal-chemotherapy enhancing tumor immunotherapy by multifunctional metal-organic framework based drug delivery system. Nano Lett 2021;21:7796-805.
97. Liu J, Yuan Y, Cheng Y, et al. Copper-based metal-organic framework overcomes cancer chemoresistance through systemically disrupting dynamically balanced cellular redox homeostasis. J Am Chem Soc 2022;144:4799-809.
98. Hidalgo T, Alonso-Nocelo M, Bouzo BL, et al. Biocompatible iron(III) carboxylate metal-organic frameworks as promising RNA nanocarriers. Nanoscale 2020;12:4839-45.
99. Lei Z, Ju Y, Lin Y, et al. Reactive oxygen species synergistic pH/H2O2-responsive poly(l-lactic acid)-block-poly(sodium 4-styrenesulfonate)/citrate-Fe(III)@ZIF-8 hybrid nanocomposites for controlled drug release. ACS Appl Bio Mater 2019;2:3648-58.
100. Zhu Y, Xin N, Qiao Z, et al. Bioactive MOFs based theranostic agent for highly effective combination of multimodal imaging and chemo-phototherapy. Adv Healthc Mater 2020;9:e2000205.
101. Cheng Y, Wen C, Sun Y, Yu H, Yin X. Mixed-metal MOF-derived hollow porous nanocomposite for trimodality imaging guided reactive oxygen species-augmented synergistic therapy. Adv Funct Mater 2021;31:2104378.
102. Li S, Chen Z, Tan L, et al. MOF@COF nanocapsule for the enhanced microwave thermal-dynamic therapy and anti-angiogenesis of colorectal cancer. Biomaterials 2022;283:121472.
103. Wang D, Jana D, Zhao Y. Metal-organic framework derived nanozymes in biomedicine. Acc Chem Res 2020;53:1389-400.
104. Feng L, Wang K, Joseph E, Zhou H. Catalytic porphyrin framework compounds. Trends in Chemistry 2020;2:555-68.
105. Huang N, Yuan S, Drake H, et al. Systematic engineering of single substitution in zirconium metal-organic frameworks toward high-performance catalysis. J Am Chem Soc 2017;139:18590-7.
106. Zhao Y, Qi S, Niu Z, et al. Robust corrole-based metal-organic frameworks with rare 9-connected Zr/Hf-Oxo clusters. J Am Chem Soc 2019;141:14443-50.
107. Zhang H, Jiang W, Liu R, et al. Rational design of metal organic framework nanocarrier-based codelivery system of doxorubicin hydrochloride/verapamil hydrochloride for overcoming multidrug resistance with efficient targeted cancer therapy. ACS Appl Mater Interfaces 2017;9:19687-97.
108. Cheng G, Li W, Ha L, et al. Self-assembly of extracellular vesicle-like metal-organic framework nanoparticles for protection and intracellular delivery of biofunctional proteins. J Am Chem Soc 2018;140:7282-91.
109. Cheng H, Jiang XY, Zheng RR, et al. A biomimetic cascade nanoreactor for tumor targeted starvation therapy-amplified chemotherapy. Biomaterials 2019;195:75-85.
110. Liu P, Zhou Y, Shi X, et al. A cyclic nano-reactor achieving enhanced photodynamic tumor therapy by reversing multiple resistances. J Nanobiotechnology 2021;19:149.
111. Li J, Shu X, Xu J, et al. S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy. Nat Commun 2022;13:1481.
112. Yu Z, Zhou P, Pan W, Li N, Tang B. A biomimetic nanoreactor for synergistic chemiexcited photodynamic therapy and starvation therapy against tumor metastasis. Nat Commun 2018;9:5044.
113. Jaaks P, Coker EA, Vis DJ, et al. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature 2022;603:166-73.
114. Ling D, Li H, Xi W, et al. Heterodimers made of metal-organic frameworks and upconversion nanoparticles for bioimaging and pH-responsive dual-drug delivery. J Mater Chem B 2020;8:1316-25.
115. Zhang SM, Cai WL, Liu X, et al. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. Nature 2021;598:682-7.
116. Larsen BD, Benada J, Yung PYK, et al. Cancer cells use self-inflicted DNA breaks to evade growth limits imposed by genotoxic stress. Science 2022;376:476-83.
117. Cao X, Chen J, Li B, et al. Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. Sci Adv 2022;8:eabl9171.
